Recently, the pan-Canadian Pharmaceutical Alliance (pCPA) annonced that it has reached a deal with generic drug makers to cut the prices of dozens of popular medications in exchange for an agreement that no jurisdiction will move to a system of public tendering for its drugs. In addition to the nationwide generic price cut, the province of Quebec also announced that it is the most recent Canadian area to add biosimilar etanercept (Erelzi) to its formulary.
Recently, the pan-Canadian Pharmaceutical Alliance (pCPA)—the organization that negotiates group discounts on behalf of Canada’s public drug plans—announced that it has reached a deal with generic drug makers to cut the prices of dozens of popular medications in exchange for an agreement that no jurisdiction will move to a system of public tendering for its drugs. This announcement comes less than a year after Quebec suggested a move to a system in which drug companies submit bids to become the sole suppliers of particular medications.
Under the new deal, companies agreed to drop the prices of nearly 70 of Canada’s top-selling, off-patent drugs by between 25% to 40% as of April 1. These price cuts are said to be worth about $1.5 billion over the next 5 years, when the deal expires. The most widely used drugs on the list treat high cholesterol, high blood pressure, and depression.
“Whether [individuals] are covered under a public/provincial drug plan or an employer-sponsored drug plan, or if they have no drug plan at all—the new prices apply to them,” said Jeff Connell, vice president of corporate affairs for the Canadian Generic Pharmaceutical Association in a statement.
This arrangement is expected to save patients $385 million in its first year and $3 billion over 5 years through both the price cuts and the industry’s promise to bring more innovative, money-saving generics to market.
In addition to the nationwide generic price cut, the province of Quebec also announced that it is the most recent Canadian area to add biosimilar etanercept (Erelzi) to its formulary of exception drugs covered by the province’s Public Prescription Drug Insurance Plan for the treatment of multiple inflammatory diseases.
Erelzi is reimbursed in this plan under specific criteria for the treatment of moderately to severely active rheumatoid arthritis (RA) in adults, and for reducing signs and symptoms of ankylosing spondylitis (AS). Erelzi will be available in a pre-filled syringe or a pre-filled pen presentation.
Quebec is the second Canadian province to add the etanercept biosimilar to its public drug plan in recent days; Ontario announced the addition of the biosimilar in December 2017. Both provinces’ plans reimburse the drug under the same criteria.
Sandoz, maker of the biosimilar Erelzi, “…is pleased that Quebec recognizes the important impact access to Erelzi can have on reducing the burden of diseases and delivering important savings to the healthcare system and the public drug plan,” said Nadia Turchetta, executive director of biopharmaceuticals for Sandoz Canada in a statement.
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.